Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab-rezetecan”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Looking for participantsNCT07100600
What this trial is testing

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

Who this might be right for
HER2-positive Advanced Breast CancerBrain MetastasesRadiotherapy
Henan Cancer Hospital 224
Testing effectiveness (Phase 2)Looking for participantsNCT07241793
What this trial is testing

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Who this might be right for
Urothelial CarcinomaAdvanced Urothelial CarcinomaUrothelial Carcinoma Recurrent
Sun Yat-sen University 96
Testing effectiveness (Phase 2)Looking for participantsNCT07383818
What this trial is testing

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Who this might be right for
HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University 111
Not applicableLooking for participantsNCT07358182
What this trial is testing

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Who this might be right for
Trastuzumab-rezetecanHER2-low Breast CancerHER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778
What this trial is testing

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Testing effectiveness (Phase 2)Looking for participantsNCT07340398
What this trial is testing

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University 200
Testing effectiveness (Phase 2)Looking for participantsNCT07309770
What this trial is testing

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Who this might be right for
Urachal CancerAdvanced Solid Tumor CancerAntibody-drug Conjugates
Sheng Zhang 90
Testing effectiveness (Phase 2)Looking for participantsNCT07037199
What this trial is testing

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 45
Not applicableActive Not RecruitingNCT07387874
What this trial is testing

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Who this might be right for
Recurrent or Metastatic Solid Tumors
Lixiaoling 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07203729
What this trial is testing

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Who this might be right for
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 184
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07129018
What this trial is testing

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer (BTC)First-line Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07047755
What this trial is testing

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer
Henan Cancer Hospital 48